ChemicalBook CAS DataBase List Cetrelimab

Cetrelimab

Product NameCetrelimab
CAS2050478-92-5
CBNumberCB28081085
MW0
MOL FileMol file
MSDS FileSDS

Chemical Properties

form	Liquid
color	Colorless to light yellow
FDA UNII	LYK98WP91F
NCI Drug Dictionary	cetrelimab

Cetrelimab Price

Product number	Packaging	Price	Product description	Buy
ChemScene CS-0628014	1mg	$325	Cetrelimab ≥99.0%	Buy
ChemScene CS-0628014	5mg	$845	Cetrelimab ≥99.0%	Buy
ChemScene CS-0628014	10mg	$1354	Cetrelimab ≥99.0%	Buy
aablocks AA02A884	1mg	$572	Cetrelimab ≥95%(SDS-PAGE&SEC-HPLC)	Buy
aablocks AA02A884	5mg	$1334	Cetrelimab ≥95%(SDS-PAGE&SEC-HPLC)	Buy

Cetrelimab Chemical Properties,Usage,Production

Uses

Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo[1].

in vivo

Cetrelimab (10 mg/kg; i.p.; single dose) has antitumor efficacy, and decreases tumor volume in PD-1 knock-in (hPD-1KI) mice with MC38 tumor^[1].
Cetrelimab (10 mg/kg; i.p.; once every 5 days for 30 d) results significant increases in peripheral blood CD8⁺ T cells in patient-derived xenograft (PDX) lung model in mice^[1].
Cetrelimab (10-100 mg/kg; i.v.; once weekly for 5 weeks) has well tolerance in cynomolgus model^[1].
Cetrelimab (0.1-10 mg/kg; i.v.; single dose, monitored for 57 d) shows an nonlinear pharmacokinetics (PK) in cynomolgus, possibly attributable to target-mediated drug deposition (TMDD)^[1].

Animal Model:	hPD-1KI model with mouse PD-1 ECD replaced by the human PD-1 ECD^[1]
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; single dose at day 7 after tumor implantation
Result:	hPD-1KI mice develop normally and have no immune abnormalities. Significantly lowered tumor volume at Day 21.

Animal Model:	Patient-derived xenograft (PDX) LG1306 lung model in mice^[1]
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; every 5 days for 6 cycles
Result:	Significantly reduced patient-derived tumor volume by 32%.

Animal Model:	Good Laboratory Practice (GLP) toxicity study in cynomolgus^[1]
Dosage:	0, 10, 30, or 100 mg/kg
Administration:	Intravenous injection; once weekly for 5 weeks
Result:	Showed well tolerance in cynomolgus.

References

[1] DeAngelis N, et al. Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models. Cancer Chemother Pharmacol. 2022 Apr;89(4):515-527. DOI:10.1007/s00280-022-04415-5

Preparation Products And Raw materials

Cetrelimab Suppliers

Supplier	Tel	Email	Country	ProdList	Advantage
Shanghai YuanYe Biotechnology Co., Ltd.	18916372613	yanzihan@shyuanye.com	China	87240	60
ShangHai Biochempartner Co.,Ltd	177-54423994 17754423994	2853530910@QQ.com	China	7996	62
Guangzhou Hongyuan Chemical Co.,Ltd	15817493340	981810490@qq.com	China	1577	58
Wuhan Chemstan Biotechnology Co., Ltd.	027-65317797 15926423062	422450190@qq.com	China	10302	58
Beijing Jin Ming Biotechnology Co., Ltd.	010-60605840	psaitong@jm-bio.com	China	27626	58
TargetMol Chemicals Inc.	4008200310 15002144251	marketing@tsbiochem.com	China	24951	58
Biolab Reagents	027-65279366 18108604356	products@biolabreagent.com	China	9864	58
Wuhan Jingkangen Biomedical Technology Co., Ltd	13720134139 086-15871494362 13720134139	orders@jknbiochem.com	China	7284	58
Shanghai Yifei Biotechnology Co. , Ltd.	021-65675885 18964387627	customer_service@efebio.com	China	11963	58
Wuhan Acumen Bio-Technology Co.,ltd	027-027-16602739303 16602739303	673003916@qq.com	China	4622	58

2050478-92-5, CetrelimabRelated Search

Send Inquiry